BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 21635149)

  • 1. Anthracycline cardiotoxicity.
    Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.
    Zerra P; Cochran TR; Franco VI; Lipshultz SE
    Expert Opin Pharmacother; 2013 Aug; 14(11):1497-513. PubMed ID: 23705955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
    Minotti G; Menna P; Salvatorelli E; Cairo G; Gianni L
    Pharmacol Rev; 2004 Jun; 56(2):185-229. PubMed ID: 15169927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
    Menna P; Minotti G; Salvatorelli E
    Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity and cardioprotection in childhood cancer.
    Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
    Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
    Ky B; Carver JR
    Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiotoxicity of anthracyclines: mechanisms and pharmacologic targets for prevention].
    Andrieu-Abadie N
    Therapie; 2004; 59(1):121-6. PubMed ID: 15199678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline cardiotoxicity: from bench to bedside.
    Gianni L; Herman EH; Lipshultz SE; Minotti G; Sarvazyan N; Sawyer DB
    J Clin Oncol; 2008 Aug; 26(22):3777-84. PubMed ID: 18669466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
    Vejpongsa P; Yeh ET
    J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer agents and cardiotoxicity.
    Ng R; Better N; Green MD
    Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content.
    Oliveira GH; Al-Kindi SG; Caimi PF; Lazarus HM
    Blood Rev; 2016 May; 30(3):169-78. PubMed ID: 26578029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ranolazine in the prevention of anthracycline-related cardiotoxicity].
    Corradi F; Paolini L; De Caterina R
    G Ital Cardiol (Rome); 2013 Jun; 14(6):424-37. PubMed ID: 23748539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.